Rapid expansion forecast for global Cushing's syndrome drug market

29 January 2015

The global Cushing’s syndrome (CS) treatment market will expand rapidly in value from around $179 million in 2013 to $499 million by 2018, representing an impressive compound annual growth rate (CAGR) of 22.74%, according to a new study

Research and consulting firm GlobalData’s latest report states that of the six major markets (6MM: the USA, France, Germany, Italy, Spain and the UK), the USA was the largest contributor to CS treatment revenues in 2013, generating around $129 million. The USA will see this figure rocket to $371 million by 2018, claiming a 74% share of the global market.

Market will be driven by new arrivals Signifor and NormoCort

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK